Fusion proteins comprising flagellin and dengue viral envelope proteins
AssigneeVanInnate Corporation
InventorsThomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
Life of this patent
Estimating the term…
Abstract
Fusion proteins comprise at least a portion of at least one flagellin and at least a portion of at least one Dengue viral envelope protein. The fusion proteins are used to stimulate an immune response and protective immunity in a subject.
Claims19
A non-glycosylated fusion protein comprising a portion of at least one flagellin selected from the group consisting of a Salmonella typhimurium flagellin type 2 (fljB/STF2), an E. coli fliC, and a S. muenchen fliC and at least a portion of at least one Dengue viral envelope protein selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein, wherein the portion of the flagellin is a Toll-like Receptor 5 agonist, the portion of the Dengue viral envelope protein is an antigen, and wherein the fusion protein activates Toll-like Receptor 5 and induces antibodies that neutralize a Dengue virus.
A non-glycosylated, recombinant fusion protein comprising a portion of at least one flagellin selected from the group consisting of a Salmonella typhimurium flagellin type 2 (fljB/STF2), an E. coli fliC, and a S. muenchen fliC and at least a portion of at least one Dengue viral envelope protein selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein, wherein the portion of the flagellin is a Toll-like Receptor 5 agonist, the portion of the viral envelope protein is an antigen and wherein the fusion protein activates Toll-like Receptor 5 and induces antibodies that neutralize a Dengue virus.
Dependencies are inferred from the claim text.